Palvella Therapeutics is set to expand its 24-week Phase III SELVA trial to include subjects aged three to five years old for ...

The Fast Track designation is supported by data from a phase 2 trial that evaluated eRapa in 30 adult patients with FAP.

Aubrey de Grey had a large mouse study of combinations of antiaging treatments. They did show that combination treatments did ...

WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) announced the expansion of SELVA, its Phase 3 clinical trial of ...

CARDIFF, UK / ACCESS Newswire / February 12, 2025 /Biodexa Pharmaceuticals PLC. (NASDAQ:BDRX), a clinical-stage ...

Palvella Therapeutics (PVLA) announced that it will expand SELVA, the Company’s Phase 3 clinical trial of QTORIN 3.9% rapamycin anhydrous gel ...

H.C. Wainwright reaffirmed a Buy rating and a $38.00 price target for Palvella Therapeutics (NASDAQ: PVLA) shares. Currently trading at $15.72, the stock has shown strong momentum with a 31% gain year ...

除TD Cowen外，H.C. Wainwright也重申了对Palvella Therapeutics的积极立场，维持买入评级和38.00美元的目标价。该公司特别关注QTORIN rapamycin在治疗皮肤静脉畸形方面的潜力，以实现公司的销售目标。

Biodexa Pharmaceuticals (BDRX) received Fast Track status from the U.S. Food and Drug Administration for eRapa, a proprietary encapsulated form ...

CARDIFF, UK / ACCESS Newswire / February 12, 2025 / Biodexa Pharmaceuticals PLC. (NASDAQ:BDRX), a clinical-stage biopharmaceutical company developing a pipeline of innovative products for the treatmen ...